Control of Cell Cycle and Cell Proliferation: 1ed

Control of Cell Cycle and Cell Proliferation, Volume 135 in the Advances in Protein Chemistry and Structural Biology series, presents chapters on a variety topics, including Exploiting pivotal mechanisms behind the senescence-like cell cycle arrest, Viral infection on through Cell Cycle Regulation, Analyzing drug resistant mutation in CDK4 gene and identification of potential inhibitors through structure based virtual screening approach, Controlling cell proliferation by targeting CDK6 using drug repurposing approach, The role of the nucleolus in regulating cell cycle, Chromatin regulators in DNA replication and genome stability maintenance during S-phase, Role of macrophage in cancer cell progression and targeted immunotherapies, and much more.

• Provides the authority and expertise of leading contributors from an international board of authors
• Presents the latest release in the Advances in Protein Chemistry and Structural Biology series
• Includes the latest information on Control of Cell Cycle and Cell Proliferation

Rossen Donev received his PhD degree in 1999 from the Institute of Molecular Biology, Bulgarian Academy of Sciences. He did postdoctoral training at Imperial Cancer Research Fund, UK (renamed after the merger with Cancer Research Campaign to Cancer Research UK, London Research Institute) and Cardiff University. In 2007 he was awarded a New Investigator Grant Award from the Medical Research Council (UK) to establish himself as an independent Principle Investigator. In 2010 Dr. Donev was appointed Senior Lecturer at Swansea University. In 2016 Dr. Donev joined MicroPharm Ltd (UK) where currently he is Head of Research. He has published more than 60 research papers, chaired scientific meetings and given invited plenary talks. Rossen Donev has consulted on projects related to development of treatments for neurodevelopmental disorders and cancer therapies. He serves as Editor-in-Chief of the Advances in Protein Chemistry and Structural Biology and on editorial board of several other journals. His research interests include signaling pathways involved in neuropsychiatric disorders and tumor escape from the immune system, and development of therapeutic strategies for their treatment. More recently he has focused on development of immunotherapeutics for non-systemic applications.